Lilly, Amylin, Merck Diabetes Drug Risks Highlighted
Hope for the diabetes drug Bydureon -- developed by Amylin Pharmaceuticals (AMLN) Eli Lilly (LLY) and Alkermes (ALKS) -- has ebbed and flowed over the past year. Last October the drug a once-weekly version of Amylin’s Byetta to control blood-sugar levels was rejected by the Food and Drug Administration. Earlier this year a head-to-head study with Novo Nordisk’s (NVO) already-approved Victoza showed the rival drug worked better. (See Amylin’s Bydureon Bombs.) Just yesterday Lilly and Amylin said studies show diabetics on Bydureon can reduce cardiovascular risks such as high blood pressure. The research is being submitted at a major diabetes ...
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here